NCT02296918View on ClinicalTrials.gov

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

December 22, 2014

Primary Completion Date

August 20, 2021

Study Completion Date

September 6, 2027

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaProlymphocytic Leukemia
Interventions
DRUG

acalabrutinib

Participants will receive oral acalabrutinib in Cohorts 1, 2, 3, and 4. The details are mentioned in the cohort description.

DRUG

Obinutuzumab

Participants will receive intravenous obinutuzumab in Cohorts 1, 2, and 4. The details are mentioned in the cohort description.

DRUG

Venetoclax

Participants will receive oral venetoclax in Cohorts 3 and 4. The details are mentioned in the cohort description.

DRUG

Rituximab

Participants will receive intravenous rituximab in Cohort 3. The details are mentioned in the cohort description.

Trial Locations (1)

43210

Research Site, Columbus

Sponsors

Lead Sponsor

Acerta Pharma BV
All Listed Sponsors
lead

Acerta Pharma BV

INDUSTRY